- CEO Richard Pops to Provide Update on Leading CNS Pipeline,
Including New Therapeutic Approaches to Schizophrenia and Major
Depressive Disorder -
DUBLIN--(BUSINESS WIRE)--Jan. 7, 2014--
Alkermes
plc (NASDAQ: ALKS) announced today that its corporate presentation
will be webcast live at the 32nd Annual J.P. Morgan
Healthcare Conference on Tuesday, Jan. 14, 2014, at 8:00 a.m. PST (11:00
a.m. EST/4:00 p.m. GMT) from the Westin St. Francis Hotel in San
Francisco. The presentation may be accessed under the Investors tab on www.alkermes.com
and will be archived for 14 days.
Alkermes plc is a fully integrated, global biopharmaceutical company
that applies its scientific expertise and proprietary technologies to
develop innovative medicines that improve patient outcomes. The company
has a diversified portfolio of more than 20 commercial drug products and
a substantial clinical pipeline of product candidates that address
central nervous system (CNS) disorders such as addiction, schizophrenia
and depression. Headquartered in Dublin, Ireland, Alkermes plc has an
R&D center in Waltham, Massachusetts; a research and manufacturing
facility in Athlone, Ireland; and manufacturing facilities in
Gainesville, Georgia and Wilmington, Ohio. For more information, please
visit Alkermes’ website at www.alkermes.com.
Source: Alkermes plc
Alkermes
Eva Stroynowski, +1 781-609-6823
Corporate
Communications
